Personalizing Cancer Drugs: A Trend Report
San Jose, California (PRWEB) January 20, 2014
Follow us on LinkedIn – Cancer represents one of the major causes of mortality worldwide. Personalized medicine in oncology is generating significant research interest given the numerous drawbacks associated with conventional cancer treatment practices. Unmet medical needs in cancer treatment and diagnosis is driving strong investments in R&D designed to unlock the untapped potential of personalized cancer drugs. Defined as a drug administration model based on molecular analysis of a patient’s unique genetic profile, personalized cancer drugs offer benefits such as improved patient outcome, and reduced cost burden on the healthcare system.
The trend report titled “Personalizing Cancer Drugs” announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the technology, its evolution, applications, future prospects, and corporate initiatives of key companies worldwide. Also covered are companies such as Cell Therapeutics Inc., F. Hoffmann-La Roche Ltd., and H3 Biomedicine, Inc., among others.
For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=141065
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/